See the latest news and media coverage for Revvity. We track all announcements, press releases, and industry mentions in real time, all in one place.
Health science technologies and services company
revvity.comLast updated
In short: Revvity reported strong 2026 financial results, raised its annual guidance, and announced the divestiture of its China immunodiagnostics.
This strategic move integrates HCD's human pancreatic beta cell models with Revvity’s detection technologies to support next-generation GLP-1 therapies, expected to close in Q4 2026.
Revenue reached $730 million, adjusted EPS hit $1.41, and guidance was raised; it also agreed to divest China Immunodiagnostics.
The platform is designed for high-volume latent tuberculosis IGRA testing in clinical labs, improving workflow efficiency and scalability.
The announcement followed a visit to Revvity's Turku site and strategic dialogues with Kenyan and Finnish officials.
Revvity Inc. stocks have been trading up by 8.14 percent following upbeat earnings and guidance that exceeded market ...
Revvity surges 6.99% today to $137.51 as shares break key levels on strategic moves and Human Cell Design acquisition.
In a report released yesterday, from UBS initiated coverage with a Hold rating on Revvity and a price target of $140.00. The company's shares closed...
On Monday, September 14, 2026, Revvity (RVTY) detailed the profound transformation the company has undergone in recent years at the 24th Annual Global Healthcare Conference hosted by Morgan Stanley. Management stated that the company has shifted its business focus to differentiated life sciences and diagnostic products, while also acknowledging uneven demand across some end markets and a protracted process for divesting its China operations...
Track Revvity and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Revvity and other trending companies.